Effects of buprenorphine and hepatitis c on liver enzymes in adolescents and young adults

Journal of Addiction Medicine

Volumn 4, Issue 4, 2010, Pages 211-216

  Bogenschutz, Michael P ^a,b   Abbott, Patrick J ^a   Kushner, Robert ^a,b   Tonigan, J Scott ^b   Woody, George E ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

Adolescent; Buprenorphine; Hepatitis C; Heroin; Opioid dependence

Indexed keywords

EID: 79954564154     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181c4e27e     Document Type: Article

References (19)

1. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346-350. (Pubitemid 32176462)
2. Diaz T, Des Jarlais DC, Vlahov D, et al. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York city. Am J Public Health 2001;91:23-30. (Pubitemid 32049262)
3. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-339. (Pubitemid 43345358)
4. Herve S, Riachi G, Noblet C, et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004;16:1033-1037. (Pubitemid 39411122)
5. Houdret N, Asnar V, Szostak-Talbodec N, et al. [Hepatonephritis and massive ingestion of buprenorphine]. Acta Clin Belg Suppl 1999;1: 29-31.
6. Irwin MR. Human psychoneuroimmunology: 20 years of discovery. Brain Behav Immun 2008;22:129-139. (Pubitemid 350299807)
7. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future national results on adolescent drug use: Overview of key findings, 2007. NIH Publication No. 08-6418. Bethesda, MD: National Institute on Drug Abuse; 2008.
8. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial. Arch Gen Psychiatry 2005;62:1157-1164. (Pubitemid 41396941)
9. Mattick R, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;2:CD002207.
10. Miller CL, Strathdee SA, Kerr T, et al. Factors associated with early adolescent initiation into injection drug use: Implications for intervention programs. J Adolesc Health 2006;38:462-464.
11. Mills KL, Teesson M, Darke S, et al. Young people with heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat 2004;27:67-73. (Pubitemid 38829781)
12. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health 2002;92:385-387. (Pubitemid 34184825)
13. Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med 1998;17:857-872. (Pubitemid 28185165)
14. Novick DM, Ochshorn M, Ghali V, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989;250:606-610. (Pubitemid 19216146)
15. Patrick DM, Tyndall MW, Cornelisse PG, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001;165:889-895. (Pubitemid 34028226)
16. Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000;9:265-269.
17. Treatment Episode Data Set (TEDS): 1996-2006. National Admissions to Substance Abuse Treatment Services, Vol S-43, DASIS Series, DHHS Publication No. (SMA) 08-4347. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2008.
18. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA 2008;300:2003-2011.
19. Zuin M, Giorgini A, Selmi C, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis 2009; 41:e8-e10.